ArticleBMC nephrology2026
Reversible choroidal ischemia as a rare sight-threatening manifestation of microscopic polyangiitis presenting with crescentic glomerulonephritis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOcular involvement in ANCA-associated vasculitis is uncommon and usually affects the anterior segment. Posterior segment ischemic involvement, particularly choroidal perfusion disturbance, is extremely rare. We report a patient with microscopic polyangiitis (MPA) who developed bilateral visual impairment due to choroidal perfusion impairment demonstrated by fluorescein angiography (FFA), along with severe crescentic glomerulonephritis. CASE PRESENTATION: A 53-year-old woman presented with acute kidney injury, proteinuria, hematuria, elevated inflammatory markers, and p-ANCA positivity. Kidney biopsy demonstrated pauci-immune crescentic glomerulonephritis. She was treated with pulse steroids, cyclophosphamide, and plasma exchange. Ten days later, she developed bilateral visual loss. Fundus examination revealed preserved retinal vasculature without hemorrhage or exudates. FFA showed normal retinal vessel filling without vascular leakage but diffuse patchy background hypofluorescence, predominantly at the posterior pole, consistent with choroidal perfusion impairment. Immunosuppression was continued, leading to complete visual recovery and partial renal improvement.
conclusionRecognition of this entity and prompt immunosuppressive treatment may prevent irreversible vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.